David Sinclair is days away from injecting genes into a human eye to turn back time. His Harvard lab will use a cocktail of three Yamanaka genes, OSK, in a glaucoma patient - the first human epigenetic reprogramming trial. If it works, the goal is a systemic reboot: mouse studies already show OSK reversed aging in brains, kidneys, and muscles.
Sinclair describes this as a Wright Brothers moment for biology. On Moonshots with Peter Diamandis, he argues aging has no physical law and says 2026 could be the year the world learns human age reversal is possible. The target isn’t just slowing decline; it’s resetting a cell’s identity to its youthful backup copy.
“David Sinclair’s lab is days away from the first human epigenetic reprogramming trial, using a subset of three Yamanaka genes (OSK) in the eye of a patient to cure blindness, following successful mouse and monkey trials.”
- Moonshots with Peter Diamandis
Gene therapies today cost $500,000 to $2 million. Sinclair wants a pill that costs pennies. His lab used AI to screen billions of molecules and already has a proof-of-concept cocktail that reversed skin cells from a 92-year-old to a 20-year-old state. He expects human trials within months via the HealthSpan XPRIZE.
Funding almost killed the project. Political friction at Harvard nearly shuttered Sinclair’s lab after NIH grants were cut. In response, Diamandis and Sinclair launched ‘Friends of Sinclair Lab,’ a private patronage model that raised $6 million from 70 individuals. Diamandis says this allows the lab to move from idea to experiment in weeks, not years.
Peter Attia, on The Peter Attia Drive, frames the challenge: human brains evolved for social survival, not processing complex data. Scientific tools like peer review are “prosthetics for objectivity” we need because we can’t trust our unassisted judgment. For radical longevity work, Sinclair’s private funding model circumvents a grant system Attia calls retrospective and risk-averse.
“Peter Diamandis initiated the ‘Friends of Sinclair Lab’ (FOSL) to provide private, direct funding to David Sinclair's research after his government grants, totaling $1-3 million annually, were cut. FOSL has since raised approximately $6 million in annual support from around 70 members.”
- Moonshots with Peter Diamandis
The timeline is aggressive. Sinclair believes we can reach ‘longevity escape velocity’ - where tech adds more than a year of life per year lived. His personal protocol includes resveratrol, NMN, metformin, and nattokinase, which he says reverses arterial plaque. But new data shifts the consensus: genetics may dictate 50% of lifespan, not 10%. That makes genomic sequencing a clinical necessity, not a curiosity.
If OSK works in the eye, the scope expands instantly. Sinclair’s lab is already testing it for ALS and macular degeneration. The bottleneck is no longer human hypothesis generation - AI can match it - but how fast we can run the experiments AI suggests.





